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Laidlomycin is a polycyclic polyether antibiotic which possesses an inhibitory activity against various mycoplasma species1}, and is effective in controlling coccidiosis in chickens2^. It is also known as selectively inhibiting the migration of hemagglutinin glycoprotein from Golgi apparatus to the cell surface in measles virus3 To exclude the possibility that laidlomycin directly inhibits reverse transcriptase in this assay system, we added laidlomycin directly to RT assay. No change in RT values was observed at the concentration as high as lOO^g/ml (data not shown).
We had previously classified the polyethers into two groups by their inhibitory actions against primary infection.
In order to examine the mechanism of action of laidlomycin, we investigated the various treatment periods. Laidlomycin was added to H9 cells (i) 30 minutes prior to infection, (i i ) 2 hours after initial exposure to vims. As shown in the data in Figure 3 , laidlomycin had the same activity when H9 cells were pretreated with the compound before inoculation of HIV-1 as they did when they were added to H9 cells during the virus adsorption period. This result suggests that laidlomycin interferes with events after with Omniscript (Qiagen), and subjected to PCR using specific oligonucleotide primers. We used the primer The data represents the means and standard deviation of triplicate experiments. staining on the plasma membrane in untreated cells (Fig.  5b) , gpl20 expression was markedly reduced in the cells treated with laidlomycin (Fig. 5 a) Wefurther examined the effect of laidlomycin on the syncytium formation by IIIB infected H9 cells. Syncytium assays were performed by mixing 4X105 CEMcells with 4X 104 chronically IIIB infected H9 cells in the presence of laidlomycin or monensin in a 6 well plate. The plates were incubated at 37°C for 48 hours and the number of giant cells was determined by microscopic examination. As shown in Figure 6 a~c, the syncytia was completely blocked for the cells treated with 1^ag/ml laidlomycin compared to untreated cells, and monensin showed a partial inhibition for syncytium formation at that concentration.
Inhibition of syncytium formation tends to suggest that the viral glycoproteins in laidlomycin treated cells were not transported to the cell surface from Golge apparatus, and therefore not available for the binding to the CD4molecule.
It is supported by immunofluorescein staining which proved The chemical structure of monensin is very similar to that of laidlomycin, and monensin has shown to block endoproteolytic cleavage and secondary glycosylation steps of glycoprotein gpl60, which results in a reduction in SEPT. 2000 syncytium formation8'9). Therefore, it is very possible that laidlomycin has same mechanism of action against HIV replication. The results of present studies demonstrate that laidlomycin is a potent inhibitor of HIVreplication and syncytium formation in T-cell lineage cell lines.
